Anvumetostat
Investigational drug
From Wikipedia, the free encyclopedia
Anvumetostat is an investigational new drug that is being developed by Amgen for the treatment of methylthioadenosine phosphorylase (MTAP)-null solid tumors.[1] Anvumetostat acts as a PRMT5 inhibitor.[2][3][4][5]
| Clinical data | |
|---|---|
| Other names | AMG-193 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C22H19F3N4O3 |
| Molar mass | 444.414 g·mol−1 |
| 3D model (JSmol) | |
| |
| |